# Brian Finrow

> Brian Finrow is the co-founder, co-chairman and CEO of Seattle-based Lumen Bioscience, where he applies a corporate lawyer’s eye for incentives, risk and deal structure to an unconventional biotechnology platform built around engineered spirulina. After a decade advising biotech companies at Cooley and operating roles at AltAir Fuels and Adaptive Biotechnologies, he co-founded Lumen with scientist Jim Roberts in 2017. The company is vertically integrated across discovery, engineering, manufacturing and clinical development, and Finrow has become a public advocate for lower-cost biologics, preventive medicine and a less capital-intensive model of drug development.

- **Role:** Co-founder, Co-chairman and CEO at Lumen Bioscience
- **Organizations:** Lumen Bioscience, Adaptive Biotechnologies, AltAir Fuels, Cooley LLP, Washington State Bar Association, The Mountaineers
- **Education:** B.A., Political Science; B.S., Public Administration, Harding University, J.D., Harvard Law School
- **Known for:** Co-founded Lumen Bioscience in 2017 and built it into a vertically integrated clinical-stage biotechnology company., Helped establish a commercial and organizational strategy around engineered spirulina for biologic manufacturing and oral delivery., Co-authored a 2022 Nature Biotechnology paper describing development of spirulina for manufacturing and oral delivery of protein therapeutics.

## Career timeline

- **2003-2012** — Practiced corporate law at Cooley LLP, focusing on biotech financing, M&A, licensing and collaborations.
- **2012-2014** — Worked in general counsel and corporate development roles at AltAir Fuels.
- **2014-2017** — Served as Senior Vice President, General Counsel and Corporate Secretary at Adaptive Biotechnologies.
- **2017** — Co-founded Lumen Bioscience with Jim Roberts in Seattle and became CEO.
- **2022** — Co-authored Lumen’s platform paper on engineered spirulina for manufacturing and oral delivery of protein therapeutics in Nature Biotechnology.
- **2025** — Lumen completed a $30 million Series C extension and expanded its board and leadership team.
- **2026** — Published an argument that preventive and globally scaled medicine will shape biotech’s next phase.

## Achievements

- Co-founded Lumen Bioscience in 2017 and built it into a vertically integrated clinical-stage biotechnology company.
- Helped establish a commercial and organizational strategy around engineered spirulina for biologic manufacturing and oral delivery.
- Co-authored a 2022 Nature Biotechnology paper describing development of spirulina for manufacturing and oral delivery of protein therapeutics.
- Led Lumen through an oversubscribed $30 million Series C extension announced in 2025.
- Helped attract more than $185 million in platform investment reported by Lumen, including substantial non-dilutive support.
- Built a public body of writing and interviews on biotech economics, preventive medicine, antimicrobial development and manufacturing productivity.

## Latest updates

- **2026-09** — Scheduled to speak at the ISPOR Healthcare Investment Summit on evidence strategy for development-stage biotechnology companies.
- **2026-01** — Published ‘The future of biotech is preventive - and global,’ arguing that global demand and preventive medicine will shape the sector’s next phase.
- **2025-11** — Discussed Lumen’s lower-cost antibody manufacturing approach and late-stage program in an Endpoints News interview republished by Lumen.
- **2025-10** — Lumen announced board and leadership additions following completion of a $30 million Series C extension.
- **2025-09** — Published the SMART Model, a framework for assessing therapeutic-program financial resilience.

## Links

- Website: https://lumen.bio
- LinkedIn: https://www.linkedin.com/in/finrow

---

Profile page: https://yespress.io/brian-finrow
Published by YesPress — https://yespress.io
Last updated: 2026-08-27